Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids

Executive Summary

AbbVie announced positive data from the first of two pivotal Phase III studies testing the GnRH receptor antagonist, but Allergan and Myovant are among the companies also looking to bring new drugs to market.

Advertisement

Related Content

Allergan's Ulipristal, Dogged By Liver Concerns, Gets An FDA Rejection
AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access
Roivant Cuts Jobs, Reallocates Staff As It Prepares To Put New Stars In The Spotlight
AbbVie's Elagolix May Be Cost Effective, But Will Test Health Budgets – ICER
Deal Watch: Takeda Continues Shire Merger Prep With Out-License Of Relugolix Rights
HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
Richter Expects Esmya Sales To Drop 50% Following EU Restrictions Over Liver Concerns
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
Takeda Paves The Way For Myovant With Phase III Fibroid Success

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100443

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel